Vaginal Cytomegalovirus Shedding Before and After Initiation of Antiretroviral Therapy in Rakai, Uganda

Year: 2015

Type: article

Abstract: Vaginal shedding of cytomegalovirus (CMV) DNA was determined longitudinally among 96 women coinfected with human immunodeficiency virus (HIV), herpes simplex virus 2, and CMV starting antiretroviral therapy (ART) during a placebo-controlled trial of HSV-2 suppression with acyclovir in Rakai, Uganda. Vaginal CMV was detected in 75 of 96 women (78.0%) and 379 of 1080 individual visits (35.1%). ART status, higher HIV RNA viral load before ART initiation, and younger age were significantly associated with increased frequency of CMV shedding (P < .01). Compared to pre-ART, CMV shedding peaked from month 2 to month 4 after ART initiation, suggesting possible immune reconstitution inflammatory syndrome. Further studies need to determine the clinical significance of asymptomatic CMV shedding.

Source: The Journal of Infectious Diseases

DOI: 10.1093/infdis/jiv135

Authors: Sara Gianella, Andrew D. Redd, Mary K. Grabowski, Aaron A. R. Tobian, David Serwadda, Kevin Newell, Eshan U. Patel, Sarah Kalibbala, Paschal Ssebbowa, Ronald H. Gray, Thomas C. Quinn, Steven J. Reynolds

Institutions: University of California San Diego, National Institutes of Health, Johns Hopkins University, National Institute of Allergy and Infectious Diseases, Rakai Health Sciences Program, Makerere University, Frederick National Laboratory for Cancer Research, Science Applications International Corporation (United States)

Language: English

Topic: Cytomegalovirus and herpesvirus research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences

OpenAlex ID: W2118994361